WZ3146 is a potent inhibitor of mutant EGFR (Epidermal Growth Factor Receptor), particularly the T790M mutation, which is commonly found in non-small cell lung cancer (NSCLC) patients resistant to first-generation therapies such as gefitinib or erlotinib. It is utilized in cancer research to inhibit the growth of cancer cells harboring this mutation, offering a potential alternative for patients who develop resistance to initial treatments. Researchers employ WZ3146 in preclinical studies to evaluate its efficacy in blocking signaling pathways that drive tumor proliferation and metastasis. Additionally, it serves as a tool to investigate mechanisms of resistance to EGFR inhibitors and to assess its safety and effectiveness in combination with other therapies for improved lung cancer management.